Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
14TH EUROPEAN MEETING ON HIV&HEPATITIS TREATMENT STRATEGIES & ANTIVIRAL DRUG RESISTANCE ROME, ITALY • 25 - 27 MAY 2016 EVALUATION REPORT www.virology-education.com EXECUTIVE SUMMARY The 14TH EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV was held on 25- 27 May 2016 at the Roma Eventi Fontana di Trevi Conference Centre and was attended by nearly 300 participants from 40 countries. The meeting gathers a steady international community of researchers and healthcare professionals. The population of this meeting has been stable for a few consecutive years. In 2016 it was almost identical to that of last year. Professional background of the participants is reflected in the below chart: Professional Background Virologist 1% PhD Student 8% Other 16% Clinician 31% Lab technician 5% Researcher 39% “A unique forum for improved management and monitoring of HIV and Hepatitis infected patients in Europe, with evidence-based recommendations.” IMPACT 97% of the respondents indicated that the content of the workshop increased their knowledge, and 83% indicated that the workshop is beneficial for the clinical management of their patients. Furthermore, 86% of the respondents indicated that they intend to incorporate the new information into their daily practice after attending the workshop. On average, 90% of the respondents indicated that the learning objectives were met. PROGRAM The program included 18 invited lectures, 20 oral abstract presentations, two guided poster tours - in addition to the regular poster viewing sessions, a pro-con debate and two roundtable discussions. Ample time was allocated for discussion. Just as last year, 3/4 day was dedicated to Hepatitis C resistance, by way of incorporating the 11th International Workshop on Hepatitis C: Resistance and New Compounds. The presentation of Dr. Francesca Ceccherini, entitled What do we know about RAVs today (delivered as part of the HCV Resistance meeting) received the highest score (an average of 4,7 (out of 5)) on all categories. GENERAL MEETING SCORE 93% of the participants rated the meeting experience as excellent/good. 97% would recommend this meeting to their peers and 85% intend to attend next year. 30% indicated good experience by previous editions as one of the main reasons to attend the workshop. The Organizing Committee and the Organizing Secretariat are pleased with the evaluation results of the 14th edition of this meeting and are looking forward to an even more successful edition in 2017! EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 2 CONTENT Executive Summary............................................................................... 2 Introduction............................................................................................ 4 Background..............................................................................................4 Unique Meeting Features........................................................................4 Target Audience.......................................................................................4 CME Accreditation...................................................................................4 Meeting Objectives...................................................................................5 Learning Objectives.................................................................................5 Meeting Partners................................................................................... 6 Commercial Supporters........................................................................ 7 Organizing Committee........................................................................... 8 Scientific Committee ...........................................................................10 Participants’ Feedback.........................................................................12 Learning Objectives...............................................................................12 General Event Experience.....................................................................12 Lectures.................................................................................................13 Guided Poster Tour................................................................................18 Organization...........................................................................................19 Publicity.................................................................................................19 Meeting demographics.........................................................................20 Number of Participants.........................................................................20 Professional Background......................................................................20 Conclusion............................................................................................21 List of Participants................................................................................22 EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 3 INTRODUCTION This is the evaluation report of the 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, held on 25 - 27 May 2016 at the Roma Eventi - Fontana di Trevi Conference Center. The Organizing Commitee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were asked to complete an evaluation form to share their opinion on several subjects. Average response rate to this survey was 50%. BACKGROUND The European HIV and Hepatitis meeting was started 14 years ago with the objective to provide infectious disease clinicians and clinical virologists involved in clinical practice and research with an opportunity to share data and discuss their clinical application. Originally the focus was on HIV but over the years with the developments in the viral hepatitis field HCV and HBV were added. The focus for each of these infections is on treatment of mono - infection. In the last decade the meeting has been able to capture a constant group of leading clinicians and researchers from Europe. As such, this meeting is the only European platform where infectious disease doctors and clinical virologists get together on an annual basis to have more in depth discussions regarding the developments in antiviral therapy. FORMAT This 2,5 day international, abstract-driven scientific and educational workshop consisted of invited lectures, round-table discussions, abstract- driven presentations and poster sessions. In order to ascertain an interactive workshop setting, much time was allocated to discussions. From 2015, the meeting incorporates the International Workshop on Hepatitis C: Resistance and New Compounds as a half-day program on Day 2. UNIQUE MEETING FEATURES The European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance is a unique European platform for clinicians and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care. TARGET AUDIENCE • Clinicians involved in daily care of individuals infected with HIV, HCV and HBV; • Scientists involved in antiviral drug development; • Researchers; • Post-graduate students. CME ACCREDITATION The 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance was designated for a maximum of 15 hours of European external CME credits. EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 4 INTRODUCTION MEETING OBJECTIVES • To gather professionals in the field of infectious diseases and clinical virology in an interactive workshop setting; • To provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development; • To map all current studies and results; • To translate new data to treatment guidelines; • To educate clinicians on how to best implement current and new drugs in clinical practice. LEARNING OBJECTIVES After participating in this activity, the participants will: • Have a thorough knowledge of the most recent results in drug development (including most recent clinical trials results) for HIV, HCV and HBV; • Be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals; • Recognize the future challenges in screening, monitoring and diagnosis of HIV and of HCV or HBV infected patients. EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 5 MEETING PARTNERS IN COLLABORATION WITH UNDER THE AUSPICES OF ENDORSED BY ACADEMIC SUPPORTERS EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 6 COMMERCIAL SUPPORTERS Financial support for the 14TH EUROPEAN MEETING ON HIV & HEPATITIS - TREATMENT STRATEGIES & ANTIVIRAL DRUG RESISTANCE was provided by the following companies: TITANIUM LEVEL GOLD LEVEL EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 7 ORGANIZING COMMITTEE CHARLES BOUCHER, MD, PHD FRANCESCA CECCHERINI - SILBERSTEIN, PHD Erasmus Medical Center, Rotterdam, the Netherlands University of Rome “Tor Vergata”, Italy STÉPHANE CHEVALIEZ, PHARMD, PHD ANDREA DE LUCA, MD Hôpital Henri Mondor, Université Paris XII, Paris, France Catholic University of the Sacred Heart, Rome and University Hospital of Siena, Italy STEPHAN DRESSLER, MD, PHD ANNA-MARIA GERETTI, MD, PHD European AIDS Treatment Group, Berlin, Germany University of Liverpool, Institute of Infection and Global Health, Liverpool, UK ROGER PAREDES, MD, PHD JEAN-MICHEL PAWLOTSKY, MD, PHD Irsi Caixa Foundation, Barcelona, Spain Hôpital Henri Mondor, Université Paris XII, Paris, France EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 8 ORGANIZING COMMITTEE CARLO FEDERICO PERNO, MD, PHD JONATHAN SCHAPIRO, MD University of Rome “Tor Vergata “, Rome, Italy Sheba Medical Center, Tel Aviv, Israel ANNE - MIEKE VANDAMME, PHD LINOS VANDEKERCKHOVE, MD, PHD Katholieke Universiteit Leuven, Belgium University Hospital of Gent, Belgium JENS VERHEYEN, MD ANNEMARIE WENSING, MD, PHD University Clinic Essen, Germany University Medical Centre Utrecht, the Netherlands STEFAN ZEUZEM, MD J.W. Goethe University Hospital, Frankfurt, Germany EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 9 SCIENTIFIC COMMITTEE Jan Albert, MD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . IMPI Karolinska Institute, Sweden Claudia Balotta, MD. . . . . . . . . . . . . . . . . . . . . . . . . University of Milan, Italy Carlos Beltran, MD . . . . . . . . . . . . . . . . . . . . . . . . . Chilean AIDS Group, Chile Marina Bobkova, PhD . . . . . . . . . . . . . . . . . . . . . . Ivanovsky Institute of Virology, Russia Ricardo Camacho, PhD. . . . . . . . . . . . . . . . . . . . . . Hospital Egas Moniz, Portugal Bonaventura Clotet, MD, PhD. . . . . . . . . . . . . . . . . Irsi Caixa Foundation, Barcelona, Spain Rolf Kaiser, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . . . University of Cologne, Germany Leon Kostrikis, PhD. . . . . . . . . . . . . . . . . . . . . . . . . University of Cyprus, Cyprus Clive Loveday, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . ICVC Charitable Trust, Clinical Virology, United Kingdom Jens Lundgren, MD. . . . . . . . . . . . . . . . . . . . . . . . . National University Hospital & University of Copenhagen, Denmark Anne-Genevieve Marcelin, PharmD, PhD. . . . . . . UPMC, France Claus Nielsen, MD, PhD . . . . . . . . . . . . . . . . . . . . . Statens Serum Institut, Denmark Monique Nijhuis, PhD. . . . . . . . . . . . . . . . . . . . . . . University Medical Center Utrecht, The Netherlands Dimitris Paraskevis, PhD . . . . . . . . . . . . . . . . . . . . University of Athens, Medical School, Greece Mario Poljak, MD, PhD. . . . . . . . . . . . . . . . . . . . . . Institute for Microbiology and Immunology, Slovenia Elisabeth Puchhammer, MD. . . . . . . . . . . . . . . . . . University of Vienna, Austria Jürgen Rockstroh, MD. . . . . . . . . . . . . . . . . . . . . . University of Bonn, Germany Christophe Rodriguez, MD . . . . . . . . . . . . . . . . . . . Hôpital Henri Mondor, France Gary Rubin, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . University of Toronto, Canada Jean- Claude Schmit, MD, PhD . . . . . . . . . . . . . . . Centre Hospitalier de Luxembourg & CRP-Santé, Luxembourg Rob Schuurman, PhD . . . . . . . . . . . . . . . . . . . . . . . University Medical Centre Utrecht, The Netherlands Anders Sönnerborg, MD, PhD . . . . . . . . . . . . . . . . Karolinska Institut, Sweden Vincent Soriano, MD, PhD. . . . . . . . . . . . . . . . . . . . Hospital Carlos III, Spain Janusz Stanczak, PhD. . . . . . . . . . . . . . . . . . . . . . . University of Warsaw, Poland Adrian Streinu - Cercel, MD, PhD . . . . . . . . . . . . . National Institute of Inf. Diseases “Prof.Dr. Matei Bals”, Romania Hauke Walter, MD. . . . . . . . . . . . . . . . . . . . . . . . . . Medizinisches Labor Dr. Berg, Germany Maurizio Zazzi, PhD . . . . . . . . . . . . . . . . . . . . . . . . University of Siena, Italy Fabien Zoulim, MD, PhD . . . . . . . . . . . . . . . . . . . . INSERM, France EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 10 COMMITTEES 11TH INTERNATIONAL WORKSHOP ON HEPATITIS C: RESISTANCE AND NEW COMPOUNDS ORGANIZING COMMITTEE CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, the Netherlands STÉPHANE CHEVALIEZ, PHARMD, PHD Hôpital Henri Mondor, Université Paris XII, Paris, France ANITA HOWE, PHD British Columbia Center for Excellence for HIV/ AIDS, Canada STEFAN ZEUZEM, MD J.W. Goethe University Hospital, Frankfurt, Germany SCIENTIFIC COMMITTEE Ralf Bartenschlager, PhD . . . . . . . . . . . . . . . . . . . University of Heidelberg, Germany Francesca Ceccherini-Silverstein, PhD . . . . . . . . University of Rome, Italy Raffaele De Francesco, PhD . . . . . . . . . . . . . . . . . Fondazione INGM, Italy Jeffrey Glenn, MD, PhD. . . . . . . . . . . . . . . . . . . . . . Stanford University, USA Eric Hughes, MD, PhD. . . . . . . . . . . . . . . . . . . . . . . Bristol-Myers Squibb Company, USA George Kukolj, PhD. . . . . . . . . . . . . . . . . . . . . . . . . Boehringer Ingelheim, Canada Michael Manns, MD. . . . . . . . . . . . . . . . . . . . . . . . . Medical School of Hannover, Germany Isabel Najera, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . Roche (Palo Alto), USA Jean-Michel Pawlotsky, MD, PhD . . . . . . . . . . . . . Hôpital Henri Mondor, France Chris Petropoulos, PhD. . . . . . . . . . . . . . . . . . . . . . Monogram Biosciences, USA Tami Pilot-Matias, PhD. . . . . . . . . . . . . . . . . . . . . . Abbvie, USA Charles Rice, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . Rockefeller University, USA Celia Schiffer, PhD. . . . . . . . . . . . . . . . . . . . . . . . . . University of Massachusetts, USA Robert Schooley, MD . . . . . . . . . . . . . . . . . . . . . . . University of California, USA David Standring, PhD Mark Sulkowski, MD. . . . . . . . . . . . . . . . . . . . . . . . Johns Hopkins University, USA Bill Symonds, PharmD . . . . . . . . . . . . . . . . . . . . . . Roivant Sciences, USA Takaji Wakita MD, PhD . . . . . . . . . . . . . . . . . . . . . . National Institute of Infectious Diseases, Japan 11th International Workshop on Hepatitis C: Resistance and New Compounds EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 26 May 2016, Rome, Italy 25 - 27 May 2016, Rome, Italy 11 11 PARTICIPANTS’ FEEDBACK INTENT TO CHANGE (Strongly) agree Neutral (Strongly) disagree The lectures have increased my knowledge of treatment strategies and antiviral drug resistance 97% 3% 0% This program is beneficial for the clinical management of my patients 83% 17% 0% I intend to incorporate the new information into the care of my patients 86% 9% 5% The following factor(s) might prevent me from implementing the gained knowledge: My patient population might not be appropriate for the implementation. 22% My current office and practice systems might not accommodate the changes. 33% My patients might have trouble complying with these changes/ strategies. 11% The medications/ procedures discussed might not be available for my patients. 22% These changes might be too time consuming. 11% LEARNING OBJECTIVES (Strongly) agree Average (Strongly) disagree Have a thorough knowledge of the most recent results in drug development (including most recent clinical trials results) for HIV, HCV and HBV 93% 7% 0% Be able to integrate the latest scientific results into daily clinical care to improve the quality of life of HIV / Hepatitis infected individuals 86% 14% 0% Excellent /very much Average/neutral Fair /disagree After completing this activity, the participants will: GENERAL EVENT EXPERIENCE agree Overall event experience 93% 7% 0% Opportunity of networking 93% 7% 0% Content of the conference 93% 7% 0% Number of invited lectures versus abstracts 79% 21% 0% Was Hep C resistance a valuable addition to the meeting? 93% 3% 2% Time allocation for discussion 100% 0% 0% Time allocation per presentation 93% 3% 2% No commercial bias (product selling) perceived 85% 11% 4% I would recommend this meeting to my peers 97% 3% 0% I plan to attend this meeting next year 85% 15% 0% EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 12 PARTICIPANTS’ FEEDBACK LECTURES WEDNESDAY 25 MAY HIV in Europe 2020 – what will it look like? Carlo Federico Perno, MD, PhD, University of Rome “Tor Vergata”, Italy Excellent / Good Average Fair / poor Interesting 99% 1% 0% Relevance 88% 7% 5% Performance 93% 6% 1% Session 1: Early ARV treatment: start early, but not too early Life-long therapy Georg Behrens, MD, PhD, Medical School Hannover, Germany Excellent / Good Average Fair / poor Interesting 91% 9% 0% Relevance 82% 16% 2% Performance 87% 11% 2% Excellent / Good Average Fair / poor Interesting 85% 15% 0% Relevance 70% 22% 8% Abstract-driven presentations: Potent Activity of GS-9883, a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance K. White O_01 Dolutegravir plus Rilpivirine in cART-Experienced Subjects: a cohort study G. Sterrantino O_02 Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects G. Sterrantino O_03 Excellent / Good Average Fair / poor Interesting 72% 18% 10% Relevance 61% 21% 18% Excellent / Good Average Fair / poor Interesting 73% 15% 12% Relevance 60% 19% 21% Excellent / Good Average Fair / poor Interesting 78% 19% 3% Relevance 67% 25% 8% Session 2: Spread of HIV drug resistance Abstract-driven presentations: Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population proportions R. Ehret O_04 EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 13 PARTICIPANTS’ FEEDBACK 3 Transmission of HIV drug resistance mutations varies regionally in Europe M. Hofstra O_05 Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/ emtricitabine/rilpivirine single tablet regimen Excellent / Good Average Fair / poor Interesting 88% 9% 3% Relevance 77% 17% 6% Excellent / Good Average Fair / poor Interesting 83% 11% 6% Relevance 72% 18% 10% Excellent / Good Average Fair / poor Interesting 79% 19% 2% Relevance 66% 24% 10% Excellent / Good Average Fair / poor Interesting 97% 3% 0% Relevance 70% 18% 12% Performance 90% 5% 5% D. Di Carlo O_06 Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R C. Callebaut O_07 Session 3: Abstract session - HBV- related HBV Cure (Educational lecture in collaboration with ESAR) Massimo Levrero, MD, University of Rome “La Sapienza”, Italy Abstract-driven presentations: Clinical impact of vaccine-escape HBsAg mutants in HBVinfected patients: high rate of atypical serological profiles and increased level of viremia and transaminases Excellent / Good Average Fair / poor Interesting 79% 16% 5% Relevance 63% 21% 16% Excellent / Good Average Fair / poor Interesting 74% 22% 4% Relevance 62% 24% 14% R. Salpini O_08 Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death A. Battisti O_09 HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression Excellent / Good Average Fair / poor Interesting 73% 22% 5% Relevance 59% 24% 17% Excellent / Good Average Fair / poor Interesting 89% 10% 1% Relevance 74% 18% 8% Performance 88% 10% 2% L. Colagrossi O_10 Session 4: Implementation of PrEP in Europe Roadblocks to implementation Pep Coll, MD, Irsi Caixa Foundation, Barcelona, Spain EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 14 PARTICIPANTS’ FEEDBACK Two cases of HIV drug resistance arising after PrEP Richard Harrigan, MD, BC Centre for Excellence in HIV/AIDS, Canada Community perspective Rebekah Webb, MA, EATG, United Kingdom Round Table discussion: experiences with implementation of PrEP Moderator: Charles Boucher Excellent / Good Average Fair / poor Interesting 89% 9% 3% Relevance 75% 12% 13% Performance 91% 9% 0% Excellent / Good Average Fair / poor Interesting 90% 9% 1% Relevance 75% 14% 11% Performance 95% 4% 1% Excellent / Good Average Fair / poor Interesting 93% 6% 1% Relevance 76% 14% 11% THURSDAY 26 MAY HIV attachment inhibitors Thomas Klimkait, PhD, University of Basel, Switzerland Excellent / Good Average Fair / poor Interesting 96% 4% 0% Relevance 78% 15% 7% Performance 96% 4% 0% Session 5: Special session - maintenance therapy Maintenance Therapy - What is known Esteban Martínez, MD, PhD, University of Barcelona, Spain Maintenance Therapy - What is the scientific / virological rationale Charles Boucher, MD, PhD, Erasmus Medical Center, the Netherlands Maintenance Therapy - What is the Future Jonathan Schapiro, MD, Sheba Medical Center, Israel Excellent / Good Average Fair / poor Interesting 100% 0% 0% Relevance 87% 6% 6% Performance 97% 3% 0% Excellent / Good Average Fair / poor Interesting 97% 3% 0% Relevance 84% 10% 6% Performance 97% 3% 0% Excellent / Good Average Fair / poor Interesting 100% 0% 0% Relevance 94% 3% 3% Performance 100% 0% 0% EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 15 PARTICIPANTS’ FEEDBACK 11TH INTERNATIONAL WORKSHOP ON HEPATITIS C: RESISTANCE AND NEW COMPOUNDS Session 1: Host-acting broad-spectrum antiviral drugs from nature Juana Díez, PhD, Universitat Pompeu Fabra, Spain How do we test for HCV RAVs (technologybased presentation) Anita Howe, PhD, British Columbia Center for Excellence for HIV/AIDS, Canada Do we need surveillance for DAA resistance: how to implement it Stephanie Popping, MD, Erasmus MC, the Netherlands Excellent / Good Average Fair / poor Interesting 77% 16% 6% Relevance 63% 17% 20% Performance 80% 10% 10% Excellent / Good Average Fair / poor Interesting 88% 13% 0% Relevance 74% 23% 3% Performance 81% 16% 3% Excellent / Good Average Fair / poor Interesting 87% 13% 0% Relevance 72% 21% 7% Performance 82% 14% 4% Session 2: What do we know about RAVs today Francesca Ceccherini - Silberstein, PhD, University of Rome ‘Tor Vergata’, Italy Excellent / Good Average Fair / poor Interesting 94% 6% 0% Relevance 94% 3% 3% Performance 94% 6% 0% Excellent / Good Average Fair / poor Interesting 89% 11% 0% Relevance 88% 8% 4% Excellent / Good Average Fair / poor Interesting 97% 3% 0% Relevance 82% 7% 11% Abstract-driven presentations: Substantial presence of natural NS3, NS5A and NS5B HCV-resistance in real practice, and their impact on direct-acting antiviral treatment in genotypes 1-4 V. Cento O_11 Characterization of Resistance-Associated Variants at baseline and failure of All-Oral Antiviral Therapy of Hepatitis C A. Lai O_12 Session 3: What do we need to know about RAVs clinically Stefan Zeuzem, MD, JW Goethe University Hospital, Germany Excellent / Good Average Fair / poor Interesting 94% 6% 0% Relevance 84% 13% 3% Performance 87% 13% 0% EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 16 PARTICIPANTS’ FEEDBACK Abstract-driven presentations: Virological failures to DAA in real life show frequent resistance associated variants and may require retreatment with unconventional regimens Excellent / Good Average Fair / poor Interesting 89% 11% 0% Relevance 88% 4% 8% Excellent / Good Average Fair / poor V. C. Di Maio O_13 Treatment emergent variants to combined direct antiviral agents therapy against hepatitis C virus F. Garcia O_14 Total HIV DNA increases in lymphomonocytes of HCV/HIV co-infected patients during and after DAA treatment I. Abbate O_15 Interesting 93% 7% 0% Relevance 88% 8% 4% Excellent / Good Average Fair / poor Interesting 76% 19% 5% Relevance 75% 10% 15% Excellent / Good Average Fair / poor Interesting 100% 0% 0% Relevance 92% 4% 4% Performance 100% 0% 0% Excellent / Good Average Fair / poor 100% 0% 0% FRIDAY 27 MAY Session 6: Remaining challenges in the optimal use of boosted PIs Pro-con Debate: Role of PIs in first line therapy PI are obsolete in first line Anna Maria Geretti, MD, PhD, University of Liverpool, UK PI remain important option for first line Linos Vandekerckhove, MD, PhD, University Hospital Gent, Belgium Improving PI drug resistance scores Jens Verheyen, MD, University Clinic Essen, Germany Interesting Relevance 92% 4% 4% Performance 88% 12% 0% Excellent / Good Average Fair / poor Interesting 96% 4% 0% Relevance 87% 4% 9% Performance 100% 0% 0% Excellent / Good Average Fair / poor Interesting 100% 0% 0% Relevance 86% 9% 5% Performance 100% 0% 0% Session 7: HIV cure strategies Diagnostic Assays Javier Martinez Picado, PhD, Irsi Caixa Foundation, Barcelona, Spain EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 17 PARTICIPANTS’ FEEDBACK Abstract-driven presentations: Ex vivo determination of stem cell transplantation graftversus-HIV reservoir effects L. Hogan O_16 Clonal Integration Site Frequency and Replication Competent Virus in Patients on ART L. Vandekerckhove O_17 Boston Project Timothy Henrich, MD, UCSF, USA Excellent / Good Average Fair / poor Interesting 90% 5% 5% Relevance 74% 11% 15% Excellent / Good Average Fair / poor Interesting 89% 11% 0% Relevance 76% 12% 12% Excellent / Good Average Fair / poor Interesting 95% 5% 0% Relevance 82% 9% 9% Performance 95% 5% 0% Excellent / Good Average Fair / poor Interesting 89% 11% 0% Relevance 67% 22% 11% Abstract-driven presentations: Viral dynamics and post-mortem analysis of HIV-1 Reservoir after Allogeneic Transplantation using Stem Cells with a nonfunctional CCR5 (CCR5 -d32) co-receptor K. Bosman O_18 Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation E. Knops O_19 Breakthrough of preexisting X4-tropic HIV after allogeneic stem-cell transplantation J. Verheyen O_20 Excellent / Good Average Fair / poor Interesting 89% 11% 0% Relevance 61% 28% 11% Excellent / Good Average Fair / poor Interesting 89% 11% 0% Relevance 72% 17% 11% Panel Discussion Members: Javier Martinez Picado, Timothy Henrich, Rolf Kaiser, Monique Nijhuis and Annemarie Wensing Excellent / Good Average Fair / poor Interesting 94% 6% 0% Relevance 69% 25% 6% GUIDED POSTER TOUR (Very much) agree Neutral (Very much) disagree Guided poster tour was a valuable addition 83% 13% 4% The posters selected for the tour were relevant 88% 8% 4% EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 18 PARTICIPANTS’ FEEDBACK ORGANIZATION Excellent/good Average Fair/poor Content of electronic announcements 86% 8% 6% Frequency of electronic announcements 84% 14% 3% Information on coference website 74% 20% 6% Online registration process 76% 19% 5% Online abstract submission process 84% 12% 4% Meeting venue 84% 16% 0% Food & Beverage 89% 8% 3% Audiovisuals 78% 14% 8% Onsite logistics 86% 11% 3% Service level of Conference Secretariat 89% 11% 0% PUBLICITY Attention was drawn to this meeting by: I a m returning pa rti cipant 30% Col l eague / word of mouth 17% Invi te from the i ndustry 2% Influenced to attend this meeting by: Experience CME Accreditation from previous edtions 3% 14% VE webs ite 19% VE-email a nnouncement 16% Invi te by fa culty members 12% Location 6% Reg. fee 2% Opportunity to meet with colleagues 19% Meeting description 19% Scientific program 37% VE i nvi tation letter Fl yer a t other 3% meetings 1% EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 19 MEETING DEMOGRAPHICS NUMBER OF PARTICIPANTS In 2015 this meeting had 287 participants from 40 countries. Largest groups were from Italy (85), Germany (16), Belgium(16) and Russia (16). The geographical distribution of participants is as follows: Australia2 Estonia1 Mexico5 Spain10 Bangladesh2 Finland4 Montenegro2 Sweden4 Belarus1 France6 Nepal1 Switzerland2 Belgium16 Germany16 Norway6 The Netherlands Brazil1 Greece4 Poland4 Turkey3 Bulgaria1 Hungary2 Portugal12 Ukraine11 Canada10 Israel2 Romania1 United Kingdom Chile5 Italy85 Russia16 USA6 Cyprus1 Latvia2 Saudi Arabia Czech Republic 1 Lithuania5 Serbia2 Denmark5 Luxembourg2 Slovenia1 14 11 2 PROFESSIONAL BACKGROUND Main activity Mainly employed by: Virologist 1% PhD Student 8% Other 16% Clinician 31% Lab technician 5% NGO Government 2% 5% Other 11% Pharma 6% University 48% Hospital 28% Researcher 39% Area of expertise: Other 3% ID 15% Hepatitis 35% HIV 47% EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 20 CONCLUSION The overall opinion of the meeting was very positive, as can be deducted from the above scores. Participants were satisfied with the scientific content of the workshop as well as with the logistics and the format of the program. The Organizing Committee and the Organizing Secretariat are very pleased with the evaluation results of this workshop. The success and importance of this workshop have underlined the need for continuation. The 15th edition of the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance is scheduled to take place on 7 - 9 May 2017 in Rome, Italy. EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 21 LIST OF PARTICIPANTS Last name, name Institute Country Abbate, Isabella Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" Roma Italy Abreu, Ricardo HPHispano-Matosinhos Portugal Acevedo Muñoz, William Hospital de Enfermedades infecciosas Dr Lucio Cordova Chile Adams, Philipp Luxembourg institute of health Luxembourg Afani, Alejandro University of Chile Chile Ahmed, Nursarat Gazi Medical college and Hospital Bangladesh Aladdin, Hassan Gilead Denmark Albert, Jan Karolinska Institutet Sweden Albini, Laura Gilead Sciences Italy Alexiev, Ivailo Nat. Center of Infectious and Parasitic Diseases Bulgaria Ali, Batool East Jeddah Hospital Saudi Arabia Alteri, Claudia University of Rome Tor Vergata Italy Amato, Maurizio ViiV Healthcare Italy Andre, Gomes Hospital Garcia de Orta Portugal Antonucci, FrancescoPaolo University of Rome Tor Vergata Italy Aragri, Marianna University of Rome Tor Vergata Italy Armenia, Daniele University of Rome Tor Vergata Italy Avanzi, Valeria Miranda Universidade Federal do Paraná Brazil Bak, Narin Royal Adelaide Hospital Australia Bakken Kran, Anne-Marte Oslo University Hospital Norway Bakó, Fruzsina St.István és St.László Kórház Hungary Baldanti, Fausto IRCCS Policlinico S. Matteo Italy Bandera, Alessandra San Gerardo Hospital Italy Bang, Didi Statens Serum Institut Denmark Bannert, Norbert Robert Koch-Institut Germany Barbaliscia, Silvia University of Rome Tor Vergata Italy Baril, Jean-Guy Clinique du Quartier Latin Canada Bartolini, Barbara Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" Roma Italy Battisti, Arianna University of Rome Tor Vergata Italy Behrens, Georg Medical School Hannover Germany Beloukas, Apostolos Institute of Infection and Global Health United Kingdom Beltrán, Carlos Chilean AIDS Group Chile Berno, Giulia University of Rome Tor Vergata Italy Bertoli, Ada University of Rome Tor Vergata Italy Berzina, Ilze Riga Eastern Clinical University Hospital, Infectology Center Latvia Bobkova, Marina Ivanovsky Institute of Virology Gamaleya Center for Epidemiology and Microbiology Russia Boccuto, Adele UNIVERSITA' DI SIENA- Policlinico Le Scotte Italy Bocket, Laurence CHRU Lille France Boggia, Nadia ViiV Healthcare Italy EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 22 Bon, Isabella Università di Bologna Italy Bondar, Borys AbbVie Ukraine Bosman, Kobus University Medical Center Utrecht UMCU The Netherlands Boucher, Charles Erasmus Medical Center The Netherlands Bozhok, Halyna Kirovograd AIDS center Ukraine Braun, Patrick Insto GmbH Germany Brunetta, Jason Maple Leaf Medical Clinic Canada Bruzzone, Bianca University of Genoa Italy Caligiuri, Patrizia Irccs Azienda Univ. Osp. San Martino Italy Callebaut, Christian Gilead USA Callegaro, Annapaola Ospedali Riuniti di Bergamo Hospital Papa Giovanni XXIII Italy Camacho, Ricardo KU Leuven Belgium Cardoso, Luis Gilead Sciences Portugal Carioti, Luca University of Rome Tor Vergata Italy Carta, Stefania University of Rome Tor Vergata Italy Carvalho, Margarida Maria CH Vila Nova Gaia Portugal Ceccherini-Silberstein, Francesca University of Rome Tor Vergata Italy Cento, Valeria University of Rome Tor Vergata Italy Chen, Alan The Ohio State University USA Chernova, Oksana Tolyatti City Clinical Hospital No. 5 Russia Chevaliez, Stéphane Hôpital Henri Mondor, Université Paris XII France Chulanov, Vladimir Central Research Institute of Epidemiology Russia Cid Silva, Purificacion Gilead Sciences Spain Cinite, Ingrida GlaxoSmithKline Latvia Circhetta, Simona Gilead Sciences Italy Colagrossi, Luna University of Rome Tor Vergata Italy Coll, Pep Hospital Universitari Germans Trias i Pujol Spain Craxì, Antonio DIBIMIS, University of Palermo Italy Cuomo, Nunzia Aorn ospedali dei colli - Cotugno Italy Cuypers, Lize Rega Institute for Medical Research Belgium Damele, Francesco Janssen Italy D'Angelo, Giulia Maria University of Rome Tor Vergata Italy De Jorge, Rocio ViiV Healthcare Spain De Luca, Andrea University of Catania Azienda Ospedaliera Senese Italy Debaisieux, Laurent ULB-Erasme Belgium Demecheleer, Els University Hospital Gent Belgium Demetriades, Ioannis Larnaca General Hospital Cyprus Depypere, Melissa UZ Brussel Belgium Devaux, Carole CRP-Santé Luxembourg Di Carlo, Daniele Sapienza - Università di Roma Italy Di Carlo, Domenico University of Rome Tor Vergata Italy Di Maio, Velia Chiara University of Rome Tor Vergata Italy Diez, Juana Univerity Pompeu Fabra Spain EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 23 Dorenberg, Dagny Haug Norwegian Institute of Public Health Norway Döring, Matthias Max Planck Institute for Informatics Germany Dressler, Stephan EATG - European AIDS Treatment Group Belgium Dupanovic, Brankica Institute of Public Health Montenegro Montenegro Dvorakova, Katerina GSK Czech Republic Dyda, Tomasz Hospital for Infectious Diseases Poland Ehret, Robert BAG MVZ mib AG & Kollegen GbR Medizinisches Labor Dr. Berg Germany Fabeni, Lavinia I.N.M.I. Lazzaro Spallanzani Italy Fabietti, Giulio ViiV Healthcare Italy Falasca, Francesca Sapienza - Università di Roma Italy Farabegoli, Patrizia AUSL Cesena Italy Fedele, Valentina University of Rome Tor Vergata Italy Feinberg, Joshua Copenhagen University Hospital Rigshospitalet Denmark Fernandes, Magda H.Sra.Oliveira-Guimarães Portugal Ferreira, Mafalda Instituto Superior de Ciências da Saúde Egas Moniz Portugal Ferrer, Pablo Universidad de Chile Chile Ferrinho, Diogo Gilead Sciences Europe United Kingdom Fimiani, Caterina Policlinico Umberto I Italy Fini, Vanessa University of Rome Tor Vergata Italy Floe, Reinhardt GlaxoSmithKline Norway Fokam, Joseph University of Rome Tor Vergata Italy Fonager, Jannik Statens Serum Institut Denmark Forbici, Federica University of Rome Tor Vergata Italy Franzese, Sonia Gilead Sciences Italy Fraser, Chris Cool Aid Clinic Canada Galizzi, Nadia Univarsità Vita-Salute - Ospedale San Raffaele Milano Italy Garcia, Federico CHU Granada; Centro PTS-San Cecilio. Inst Inv Biosanitaria Ibs-Granada. Spain Gardziuliene, Gabija Glaxo Smith Kline Lithuania Gaytán Martínez, Jesús Enrique National Medical Center "La Raza", Mexico Mexico Geretti, Anna Maria University of Liverpool Institute of Infection and Global Health United Kingdom Giannella, Sara University of Rome Tor Vergata Italy Giannini, Alessia UNIVERSITA' DI SIENA - Policlinico Le Scotte Italy Gomes, Perpetua Centro Hospitalar de Lisboa Ocidental Portugal Gori, Caterina University of Rome Tor Vergata Italy Gunduz, Alper Sisli Etfal Training and Research Hospital Turkey Haartsen, Maxim ViiV Healthcare United Kingdom Hammer, Janniche Gilead Sciences Norway Harrigan, Richard BC Centre for Excellence in HIV/AIDS Canada Hauser, Andrea Robert Koch-Institut Germany Hawkes, Jennifer Northern Health Canada Henrich, Timothy University of California, San Francisco USA EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 24 Hofstra, Marije University Medical Center Utrecht UMCU The Netherlands Hogan, Louise UCSF USA Howe, Anita Vancouver Coastal Health Authority Canada Jevtovic, Djordje Institute for Infectious and Tropical Diseases Serbia Kaiser, Rolf University of Cologne Germany Kanestrøm, Anita Norwegian Institute of Public Health Norway Kapusta, Margaryta Mykolaiv Regional State Administration Ukraine Kausas, Aidas Siauliai County Hospital Lithuania Kazennova, Elena Ivanovsky Institute of Virology Gamaleya Center for Epidemiology and Microbiolog Russia Khromova, Irina Republican Center for Prevention and Control of AIDS and Infectious Diseases Russia Klein, Alex Mount Sinai Hospital Canada Klimkait, Thomas University of Basel Switzerland Knezevic, Olgica Institute of Public Health Montenegro Montenegro Knops, Elena University of Cologne Germany Koenig, Bettina Abbvie Germany Kostaki, Evangelina University of Athens Greece Kwa, David Onze Lieve Vrouwe Gasthuis The Netherlands Kyrychenko, Tatyana Ukrainian Medical Stomatological Academy Ukraine Kyryliuk, Olga Abbvie Ukraine Laga, Vita Ivanovsky Institute of Virology Gamaleya Center for Epidemiology and Microbiology Russia Lai, Alessia University of Milan Italy Lapovok, Ilya Central Research Institute for Epidemiology Russia Lennerstrand, Johan Uppsala University Sweden Lettinga, Kamilla Onze Lieve Vrouwe Gasthuis The Netherlands Levrero, Massimo University La Sapienza Italy Lichtner, Miriam Sapienza University of Rome Italy Liitsola, Kirsi National Institute for Health and Welfare Finland Lipsi , Maria Rosaria OSPEDALI RIUNITI - FOGGIA Italy Loginova, Tetyana Narcological Hospital Socialtherapy Ukraine Longo, Serena Università di Bologna Italy Louagie, Philippe ViiV Healthcare Belgium Louis, Isabelle University Bordeaux Inserm U897- Isped France Loveday, Clive ICVC Charitable Trust United Kingdom Lübke, Nadine Institute of Virology Germany Lynn, Amber Alberta Health Services Canada Maijgren Steffensson, Catharina Gilead Sciences Sweden AB Sweden Marascio, Nadia University "Magna Graecia" Italy Martínez Picado, Javier Fundacio irsiCaixa Spain Martinez, Esteban Hospital Clinic Barcelona Spain Martiushova, Inna Tula Regional Hospital Russia Mascia, Claudia Sapienza - Università di Roma Italy EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 25 Mata-Marín, José Antonio Centro Medico Nacional "La Raza" Mexico Matsiyeuskaya, Natallia Grodno State Medical University Belarus Matulionyte, Raimonda Vilnius University Lithuania Mazzuti, Laura Sapienza - Università di Roma Italy Meini, Genny Università degli Studi di Siena Italy Micheli, Valeria University Hospital L. Sacco Italy Mölkänen, Tomi GlaxoSmithKline Finland Mor, Orna Sheba Medical Center Israel Mortier, Virginie University Hospital Gent Belgium Mudrikova, Tatiana University Medical Center Utrecht UMCU The Netherlands Nielsen, Emil Eik Copenhagen University Hospital Rigshospitalet Denmark Nieman, An-Emmie St Elisabeth Ziekenhuis The Netherlands Nijhuis, Monique University Medical Center Utrecht UMCU The Netherlands Ojha, Chet Government of Nepal Nepal Oliveira, Celia Hospital de Aveiro Portugal Oosterlaken, Tom Hologic The Netherlands Palandri, Lucia University of Rome Tor Vergata Italy Paolucci, Stefania IRCCS Policlinico S. Matteo Italy Paraskevis, Dimitrios University of Athens Greece Parczewski, Milosz Pomeranian Medical University Poland Paredes, Roger IrsiCaixa Foundation Spain Paricio, Antonio Hospital Francisco De Borja De Gandia Spain Paul, Miriam Macquarie University Australia Pereira, Rui Hospital de Faro Portugal Perno, Carlo-Federico University of Rome Tor Vergata Italy Pesic Pavlovic, Ivana Clinical Center of Serbia Serbia Petrovska, Olena Zaporizhya AIDS center Ukraine Petry, Ralph Abbvie Deutschland GmbH & Co KG Germany Piermatteo, Lorenzo University of Rome Tor Vergata Italy Pineda-Peña, Andrea Clemencia KU Leuven Belgium Pirazolli, Antonella ViiV Healthcare United Kingdom Poljak, Mario University of Ljubljana Medical Faculty Slovenia Pompei, Marco Merck Sharp and Dohme Belgium Popping, Stephanie Erasmus Medical Center The Netherlands Poretskova, Elena R-Pharm Russia Posthumus-Plantinga, Alice Virology Education The Netherlands Poveda, Eva INIBIC-Complejo Hospitalario Universitario de A Coruña Spain Poveda, Jean-Dominique Laboratoire CERBA France Prodanova, Kseniia Center of prevention and control of AIDS Russia Quercia, Romina ViiV Healthcare United Kingdom Rahman, Nawshad Muhammad Wahidur Gazi Medical college and Hospital Bangladesh Rappazzo, Emanuela San Martino Hospital University of Genoa Italy EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 26 Robinson, Chris Gilead Sciences United Kingdom Rodriguez-Diaz, Roberto Instituto Nacional de Ciencias Médicas y Nutrición Mexico Rogatto, Felipe Gilead Sciences United Kingdom Roger Schmeltz, Julien Gilead Sciences France Rosas, Antonio Pharma Investi de Chile Ss. A. Chile Rossetti, Barbara Clinic of Infectious Diseases, AOUS Italy Roxo, Joao HOSPITAL DOS CAPUCHOS Portugal Rozera, Gabriella Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" Roma Italy Rubin, Gary University of Toronto Canada Ruelle, Jean UC Louvain Belgium Ruggiero, Tina Amedeo di Savoia Hospital Italy Sabinina, Olena Poltava AIDS center Ukraine Sakalauskiene, Ugne Central Prison Hospital Lithuania Saladini, Francesco University of Siena Italy Salpini, Romina University of Rome Tor Vergata Italy Santangelo, Rosaria Catholic University Del Sacro Cuore Institute of Clinical Infectious Diseases Italy Santoro, Maria University of Rome Tor Vergata Italy Sarmometov, Evgenii Perm Regional Centre for the Fight against AIDS and infectious diseases Russia Sayan, Murat Kocaeli University Turkey Schaffer, Sven Hologic Germany Schapiro, Jonathan Sheba Medical Center Israel Schütze, Marcel MVZ mib medizinisches Infektiologiezentrum Berlin AG Germany Scutari, Rossana University of Rome Tor Vergata Italy Shevchenko, Olga Dnipropetrovsk Medical Academy Ukraine Shostakovych-Koretskaya, Liudmyla Dnipropetrovsk Medical Academy Ukraine Sikut, Rein GlaxoSmithKline Estonia Silva, Luis H. Fernando Fonseca Portugal Sönnerborg, Anders Karolinska Institutet Sweden Sorbo, Maria Chiara University of Rome Tor Vergata Italy Stanczak, Janusz Hospital for Infectious Diseases Poland Starikova, Irina Republican Center for Prevention and Control of AIDS and Infectious Diseases Russia Stasishkis, Tatiana Republican Center for Prevention and Control of AIDS and Infectious Diseases Russia Stazi, Francesca University of Rome Tor Vergata Italy Stefanova, Ina ViiV Healthcare Canada Stene-Johansen, Kathrine Norwegian Institute of Public Health Norway Stepanova, Elena Republican Center for Prevention and Control of AIDS and Infectious Diseases Russia Sterrantino, Gaetana Azienda Ospedaliera Universitaria Careggi Italy Sticchi, Laura University of Genoa Italy EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 27 Sutinen, Jussi Helsinki University Hospital Finland Tau, Pamela University Hospital L. Sacco Italy Tavares, Francisca Gilead Sciences Portugal Tudor, Ana Maria Institute for Infectious Disease M. Bals Matei Romania Ujhelyi, Eszter St.István és St.László Kórház Hungary Underwood, Mark GlaxoSmithKline USA Vandamme, Anne-Mieke Katholieke Univ. Leuven Rega Institute for Medical Research Belgium Vandekerckhove, Linos Universitair Ziekenhuis Gent UZ Belgium Vandercam, Bernard UCLouvain Belgium Vanhouteghem, Hilde AZ Maria Middelares Belgium Varna, Klaidas Abbvie Lithuania Vatteroni, Marialinda Azienda Ospedaliera Universitaria Pisana Italy Verheyen, Jens Universitätsklinikum Essen Germany Vicenti, Ilaria University of Siena Italy Villa, Giovanni University of Liverpool Institute of Infection and Global Health United Kingdom Vincenti, Donatella Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" Roma Italy Vuorte, Juha Gilead Sciences Finland Finland Wali, Ghassan King Faisal Specialist Hospital and Research Centre Saudi Arabia Walter, Hauke Germany Webb, Rebekah EATG european aids treatment group Belgium Weijer, Sebastiaan MC/groep MC Zuiderzee The Netherlands Weiser Smeke, Ariane Estrella Anahuac University, Medicine school, Mexico city, Mexico Mexico Wensing, Annemarie University Medical Center Utrecht UMCU The Netherlands White, Kirsten Gilead Sciences USA Widera, Marek Institute of Virology, University Hospital of Essen Germany Yalcinkaya Kezban Tulay, Kezban Tulay National Public Health Institution of Turkey Turkey Yurchuk, Sergey Regional Clinical Hospital of Infectious Diseases Russia Zabek, Piotr Hospital for Infectious Diseases Poland Zaccarelli, Mauro INMI L Spallanzani Italy Zadorozhna, Kateryna Kharkiv AIDS center Ukraine Zanussi, Stefania Oncology Reference Centre Italy Zazzi, Maurizio University of Siena Italy Zeuzem, Stefan JW Goethe University Hospital Germany Zingg, Maurice University of Basel Switzerland EVALUATION REPORT 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance 25 - 27 May 2016, Rome, Italy 28